Replimune Stock Rockets 100% on FDA Nod – Analysts Eye Upside
Replimune’s stock has been extremely volatile in 2025. It soared on Oct. 20 after the FDA acceptance news: shares nearly doubled from about $4.50 to $8.94 that day marketbeat.com. This reversed a mid-year collapse – in July 2025 a disappointing FDA Complete Response Letter caused the stock to collapse ~73% in one day globenewswire.com. Over the past year the 52-week trading range is roughly $2.68 to $17.00 marketbeat.com, reflecting that roller-coaster. Institutional interest remains high: recently hedge funds like TD Asset Management increased their stake in Q2 2025 marketbeat.com. Still, REPL’s year-to-date chart is choppy – it’s well below its early-2025 peak and may need to hold above key levels to sustain gains benzinga.com. As of mid-Oct. 2025, Replimune’s market capitalization is about $698 million marketbeat.com and it carries little debt. The stock trades with a high beta, mirroring broader biotech swings.
